Evidence map›Paper›PMID 32565008›Full record

Trial reportThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2021

Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments.

Krista L Lanctôt, Roberta W Scherer, Abby Li, Danielle Vieira, Hamadou Coulibaly, Paul B Rosenberg, Nathan Herrmann, Alan J Lerner, Prasad R Padala, Olga Brawman-Mintzer and 6 more

Open access · greenAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Prevalence, treatment, and neural correlates of apathy in different forms of dementia: a narrative review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Review
  5. An Update on Apathy in Alzheimer's Disease.Geriatrics (Basel, Switzerland) · 2023
    Review
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 2 countries.

Krista L LanctôtSunnybrook Research Institute, Toronto, ON, Canada. Electronic address: krista.lanctot@sunnybrook.ca.
Roberta W SchererJohns Hopkins University Bloomberg School of Public Health, Baltimore, MD.
Abby LiSunnybrook Research Institute, Toronto, ON, Canada.
Danielle VieiraSunnybrook Research Institute, Toronto, ON, Canada.
Hamadou CoulibalyJohns Hopkins University Bloomberg School of Public Health, Baltimore, MD.
Paul B RosenbergJohns Hopkins University School of Medicine, Baltimore, MD.
Nathan HerrmannSunnybrook Research Institute, Toronto, ON, Canada.
Alan J LernerUniversity Hospital - Case Western Reserve University, Cleveland, OH.
Prasad R PadalaUniversity of Arkansas for Medical Science, Central Arkansas Veterans Healthcare System, Little Rock, AR.
Olga Brawman-MintzerMedical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center, Charleston, SC.
Chris H van DyckYale University, New Haven, CT.
Anton P PorsteinssonUniversity of Rochester, Rochester, NY.
Suzanne CraftWake Forest University School of Medicine, Winston-Salem, NC.
Allan LeveyEmory University, Atlanta, GA.
William J BurkeBanner Alzheimer's Institute, Phoenix, AZ.
Jacobo E MintzerMedical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center, Charleston, SC.
Sunnybrook Research InstituteJohns Hopkins University · USBanner Alzheimer’s InstituteCase Western Reserve University · USCentral Arkansas Veterans Healthcare System · USEmory University · USJohns Hopkins Medicine · USMedical University of South Carolina · USRalph H. Johnson VA Medical Center · USUniversity of Rochester · USWake Forest University · USYale University · US

Funding

Yale Alzheimer Disease Research CenterP30AG066508 · NIA · YALE UNIVERSITY · PI STEPHEN M STRITTMATTER, CHRISTOPHER H VAN DYCK · 2020 to 2026
$30.2M
Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI MARILYN S. ALBERT · 2020 to 2026
$29.3M
Wake Forest Alzheimer's Disease Core CenterP30AG049638 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MONTINE, THOMAS J · 2016 to 2020
$12.2M
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)R01AG046543 · NIA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI HERRMANN, NATHAN, LANCTOT, KRISTA L. · 2014 to 2018
$8.1M
Using connectomics to characterize risk for Alzheimer's DiseaseR01AG055132 · NIA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI JOSEPH, JANE E, MINTZER, JACOBO · 2017 to 2021
$3.7M
Transcranial Magnetic Stimulation for Apathy in Mild Cognitive ImpairmentI01RX002638 · VA · CENTRAL ARKANSAS VETERANS HLTHCARE SYS · PI PADALA, PRASAD R. · 2019 to 2024
–
NIA NIH HHS P30 AG049638NIA NIH HHS P30 AG066507NIA NIH HHS P30 AG066508NIA NIH HHS R01 AG046543NIA NIH HHS R01 AG055132RRD VA I01 RX002638
6 · The paper itself

Abstract

backgroundDiagnostic criteria for apathy have been published but have yet to be evaluated in the context of clinical trials. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) operationalized the diagnostic criteria for apathy (DCA) into a clinician-rated questionnaire informed by interviews with the patient and caregiver.

objectiveThe goal of the present study was to compare the classification of apathy using the DCA with that using the Neuropsychiatric Inventory-apathy (NPI-apathy) subscale in ADMET 2. Comparisons between NPI-Apathy and Dementia Apathy Interview Rating (DAIR) scale, and DCA and DAIR were also explored.

methodsADMET 2 is a randomized, double-blind, placebo-controlled phase III trial examining the effects of 20 mg/day methylphenidate on symptoms of apathy over 6 months in patients with mild to moderate Alzheimer's disease (AD). Participants scoring at least 4 on the NPI-Apathy were recruited. This analysis focuses on cross-sectional correlations between baseline apathy scale scores using cross-tabulation.

resultsOf 180 participants, the median age was 76.5 years and they were predominantly white (92.8%) and male (66.1%). The mean (±standard deviation) scores were 7.7 ± 2.4 on the NPI-apathy, and 1.9 ± 0.5 on the DAIR. Of those with NPI-defined apathy, 169 (93.9%, 95% confidence interval [CI] 89.3%-96.9%) met DCA diagnostic criteria. The DCA and DAIR overlapped on apathy diagnosis for 169 participants (93.9%, 95% CI 89.3%-96.9%).

conclusionThe measurements used for the assessment of apathy in patients with AD had a high degree of overlap with the DCA. The NPI-apathy cut-off used to determine apathy in ADMET 2 selects those likely to meet DCA criteria.

Indexed as

AgedAlzheimer DiseaseApathyCaregiversCross-Sectional StudiesFemaleHumansMaleMethylphenidateMethylphenidateAlzheimer's diseaseapathydementiadiagnostic criteriamethylphenidateneuropsychiatric inventory

Identifiers

PMID32565008
PMCPMC7704818
OpenAlexW3030210213

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.